Teva Pharm Adr (TEVA) Shareholder Accipiter Capital Management LLC Has Upped Holding by $6.83 Million

March 14, 2018 - By Michael Collier

Gabe Hoffman increased its stake in Teva Pharm Adr (TEVA) by 198.89% based on its latest 2017Q3 regulatory filing with the SEC. Accipiter Capital Management Llc bought 402,040 shares as the company’s stock declined 15.11% while stock markets rallied. The hedge fund run by Gabe Hoffman held 604,185 shares of the major pharmaceuticals company at the end of 2017Q3, valued at $10.63 million, up from 202,145 at the end of the previous reported quarter. Accipiter Capital Management Llc who had been investing in Teva Pharm Adr for a number of months, seems to be bullish on the $18.88B market cap company. The stock decreased 3.91% or $0.755 during the last trading session, reaching $18.565. About 7.32 million shares traded. Teva Pharmaceutical Industries Limited (NYSE:TEVA) has declined 41.70% since March 14, 2017 and is downtrending. It has underperformed by 58.40% the S&P500.

More notable recent Teva Pharmaceutical Industries Limited (NYSE:TEVA) news were published by: which released: “It’s Time to Add Teva Pharmaceutical Industries Ltd (ADR) Stock to Your Watchlist” on February 16, 2018, also with their article: “Teva Needs More Than Job Cuts” published on December 14, 2017, published: “Trade of the Day: Teva Pharmaceutical Industries Ltd (ADR) (TEVA)” on January 31, 2018. More interesting news about Teva Pharmaceutical Industries Limited (NYSE:TEVA) were released by: and their article: “Why Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock Fell Today” published on August 03, 2017 as well as‘s news article titled: “Scoop Up Teva Pharmaceutical Industries Ltd (ADR) on Every Dip” with publication date: January 18, 2018.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Ratings Coverage

Among 35 analysts covering Teva Pharma (NYSE:TEVA), 9 have Buy rating, 8 Sell and 18 Hold. Therefore 26% are positive. Teva Pharma had 147 analyst reports since July 21, 2015 according to SRatingsIntel. On Tuesday, November 7 the stock rating was downgraded by HSBC to “Reduce”. The stock has “Equal-Weight” rating by Barclays Capital on Monday, August 7. Jefferies maintained the stock with “Buy” rating in Thursday, July 14 report. The firm has “Hold” rating given on Friday, August 4 by Maxim Group. Morgan Stanley downgraded Teva Pharmaceutical Industries Limited (NYSE:TEVA) rating on Monday, August 7. Morgan Stanley has “Underweight” rating and $16 target. The rating was maintained by RBC Capital Markets with “Buy” on Friday, June 16. The stock has “Sell” rating by Leerink Swann on Tuesday, January 2. The firm has “Hold” rating given on Thursday, July 13 by Maxim Group. The rating was upgraded by Cantor Fitzgerald to “Hold” on Friday, December 22. The firm has “Outperform” rating by Oppenheimer given on Thursday, July 14.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.